Identifying patients at risk for coronary heart disease: Treatment implications

European Heart Journal

Volumn 19, Issue 12, 1998, Pages 1776-1783

  Shepherd, James ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cholesterol lowering drugs; Coronary heart disease prevention; Diabetes mellitus; Hypertension; Menopause

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; ESTROGEN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATINE DERIVATIVE;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DIABETES MELLITUS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MYOPATHY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING;

ANTILIPEMIC AGENTS; COMORBIDITY; CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; POSTMENOPAUSE; PREVALENCE; PRIMARY PREVENTION; RISK FACTORS;

EID: 0032402557     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1122     Document Type: Review

References (73)

1. [1] National Heart, Lung, and Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung, and blood diseases - 1990. Bethesda: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1992.
2. [2] Uemura K. International trends in cardiovascular diseases in the elderly. Eur Heart J 1988; 9 (Suppl D): 1-8.
3. [3] Uemura K, Pisa Z. Trends in cardiovascular mortality in industrialized countries since 1950. World Health Stat Q 1988; 41: 155-78.
4. [4] Tuomilehto J, Kuulasmaa K, Torppa J. WHO MONICA project: geographic variation in mortality from cardiovascular disease. World Health Stat Q 1987; 40: 171-84.
5. [5] National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445.
6. [6] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology. European Atherosclerosis Society and the European Society of Hypertension. Eur Heart J 1994; 15: 1300-31.
7. [7] Butler WJ, Ostrander LD, Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985; 121: 541-7.
8. [8] Jarrett RJ, Shipley MJ. Type 2 (non-insulin dependent) diabetes mellitus and cardiovascular disease - putative association via common antecedents; further evidence from the Whitehall study. Diabetologia 1988; 31: 737-40.
9. [9] Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: associated risk factors. Diabetologia 1990; 33: 542-8.
10. [10] Kim DK, Escalante DA, Garber AJ. Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes. Clin Ther 1993; 15: 766-78.
11. [11] McKenney JM. Understanding and treating dyslipidaemia associated with non-insulin-dependent diabetes mellitus and hypertension. Pharmacotherapy 1993; 13: 340-52.
12. [12] Bierman EL. Atherosclerosis in diabetes. Arterioscler Thromb 1992; 12: 647-56.
13. [13] Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 1996; 19: 387-9.
14. [14] Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role of hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991; 121: 1283-8.
15. [15] Dean JD, Durrington PN. Treatment of dyslipoproteinaemia in diabetes mellitus. Diabetic Med 1996; 13: 297-312.
16. [16] Welborn TA. Dyslipidemia in non-insulin dependent diabetes: the need for a clinical intervention trial. Aust NZ Med 1994; 24: 61-4.
17. [17] Kannel WB. Hypertension as a risk factor for cardiac events - epidemiological results of long-term studies. J Cardiovasc Pharmacol 1993; 21 (Suppl 2): S27-37.
18. [18] Working group on the management of patients with hypertension and high blood cholesterol. National education programs working group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 1991; 114: 224-37.
19. [19] Goode GK, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345: 362-4.
20. [20] Goode GK, Heagerty AM. Cholesterol lowering therapy restores small artery endothelial function in hypercholesterolemic subjects. Circulation 1991; 83: 361-9.
21. [21] Leung W-H, Lau C-P, Wong C-K. Beneficial effects of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-500.
22. [22] Hanes DS, Weir MR. Gender considerations in hypertension pathophysiology and treatment. Am J Med 1996; 101 (Suppl 3A): 10S-21S.
23. [23] Matthews KA, Meilahn E, Kuller KH, Kelsey SF, Cagiuta AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641-6.
24. [24] Razay G, Heaton KW, Bolton DH. Coronary heart disease risk factors in relation to menopause. QJ Med 1992; 85: 307-8.
25. [25] Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-31.
26. [26] Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
27. [27] Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.
28. [28] Stampfler MJ, Colditz GA, Willett WC et al. Estrogen replacement therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-62.
29. [29] Falkenborn M, Persson I, Adami H-Q et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821-8.
30. [30] Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Arch Intern Med 1992; 117: 1016-37.
31. [31] Grover SA, Coupai L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801-6.
32. [32] Jackson R, Beaglehole R. Evidence-based management of dyslipidemia. Lancet 1995; 346: 1440-1.
33. [33] Pedersen TR. Lowering cholesterol with drugs and diet. N Engl J Med 1995; 333: 1350-1.
34. [34] West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42.
35. [35] Witztum JL. Drugs used in treatment of hyperlipoproteinemias. In: Hardman JG, Gilman AG, Limbird LE, eds. Goodman and Oilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill, 1996: 875-97.
36. [36] Rackely CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19: 683-9.
37. [37] Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
38. [38] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
39. [39] Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
40. [40] Illingworth DR. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs 1991; 41: 151-60.
41. [41] Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A reappraisal. Drug Saf 1996; 14: 11-24.
42. [42] Frick MH, Elo MO, Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
43. [43] de Faire U, Ericsson C-G, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996; 17 (Suppl F): 37-42.
44. [44] Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-118.
45. [45] Dart AM. Managing elevated blood lipid concentrations. Who, when and how? Drugs 1990; 39: 374-87.
46. [46] Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
47. [47] Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.
48. [48] Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
49. [49] Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
50. [50] American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 179-82.
51. [51] Garg A, Grundy S. Management of dyslipidaemia in NIDDM. Diabetes Care 1990; 13: 153-69.
52. [52] Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. N Engl J Med 1988; 318: 81-6.
53. [53] Kazumi T, Yoshino G, Ishida Y et al. Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 61-8.
54. [54] Knopp RH, Frohlich J, Jokubaitis LA et al. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96 (Suppl 6A): 69S-78S.
55. [55] Betteridge DJ. Diabetic dyslipidemia: treatment implications. J Intern Med 1994; 236 (Suppl 736): 47-52.
56. [56] Anonymous. Detection and management of lipid disorders in diabetes. Diabetes Care 1993; 16 (Suppl 2):: 106-12.
57. [57] Garg A, Grundy SM. Nicotinic acid as therapy for dysfunction in non-insulin dependent diabetes mellitus. JAMA 1990; 264: 723-6.
58. [58] Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins: I. Diuretics. Drugs 1986; 32: 260-78.
59. [59] Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins: I. Non-diuretic drugs. Drugs 1986; 32: 335-57.
60. [60] Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systemic review and meta-analysis. JAMA 1997; 277: 739-45.
61. [61] Joint Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-83.
62. [62] Farmer JA, Gotto Jr AM. Antihyperlipidemic agents. Drug interactions of clinical significance. Drug Saf 1994; 11: 301-9.
63. [63] Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63.
64. [64] Nabulsi AA, Folsom AR, White A et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
65. [65] Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women - the Postmenopausal Estrogen/ Progestin Interventions (PEPI) trial. JAMA 1995; 273: 199-208.
66. [66] Assmann G, Cullen P, Schulte H. HRT, plasma risk factors and cardiovascular disease. Eur Menopause J 1996; 3: 203-8.
67. [67] Munk-Jensen N, Ulrich LG, Obel EB, Nielsen SP, Edwards D, Meinertz H. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect of plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994; 171: 132-8.
68. [68] Villecco AS, De Aloysio D, Foderaro S et al. Comparison of the effects of simvastatin versus hormone replacement therapy in the treatment of postmenopausal women with primary hypercholesterolemia. Curr Ther Res 1995; 56: 515-29.
69. [69] Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-73.
70. [70] Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1112-9.
71. [71] Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995; 91: 2274-82.
72. [72] West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997; 79: 756-62.
73. [73] Caro J, Klittich W, McGuire A et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82.